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1. Introduction {#jia225008-sec-0004}
===============

Since 2013, when the World Health Organization strongly recommended the use of HIV viral load (VL) testing to monitor viral suppression in persons on antiretroviral therapy (ART) in low resource settings (LRS), the scale‐up of this diagnostic test in low‐ and middle‐income countries has been limited [1](#jia225008-bib-0001){ref-type="ref"}, [2](#jia225008-bib-0002){ref-type="ref"}. Of the estimated 19.5 million persons currently on ART in these countries, less then 40% have routine access to VL testing [3](#jia225008-bib-0003){ref-type="ref"}. This is despite the utility of this test as a means to monitor viral suppression, enable early detection of treatment failure, and guide appropriate ART management. Based on current projections, access to VL testing will reach only 60% by 2020 [3](#jia225008-bib-0003){ref-type="ref"}.

Current VL technologies are complex nucleic acid assays that require sophisticated laboratory infrastructure, advanced technical skills, well‐established sample logistics, and systems for results return [4](#jia225008-bib-0004){ref-type="ref"}. Fostering the rapid and effective use of test results is also essential to achieve expected health outcomes, especially as the test is new, and unfamiliar to many clinicians and patients. Optimizing testing capacity, enabling health systems, and the appropriate use of test results to guide treatment is the focus of governments, implementing partners, donors, industry, and civil society [5](#jia225008-bib-0005){ref-type="ref"}, [6](#jia225008-bib-0006){ref-type="ref"}. Despite these efforts, scale up of routine VL testing has encountered delays and uneven success [2](#jia225008-bib-0002){ref-type="ref"}, [7](#jia225008-bib-0007){ref-type="ref"}, [8](#jia225008-bib-0008){ref-type="ref"}, which may impede the achievement of the global 2020 HIV 90‐90‐90 goals set by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the aspiration of ending AIDS by 2030 [5](#jia225008-bib-0005){ref-type="ref"}.

The scale‐up of VL testing is not the first large‐scale implementation of an HIV‐related diagnostic test in low and middle income countries. In particular, the experience of CD4 assays and early infant HIV diagnosis (EID) testing over the past 15 years provide important lessons for VL implementation [9](#jia225008-bib-0009){ref-type="ref"}, [10](#jia225008-bib-0010){ref-type="ref"}, [11](#jia225008-bib-0011){ref-type="ref"}. This commentary reviews the use of EID and CD4 tests in RLS and identifies best practices, innovations and success factors to inform scale‐up of VL services in these same settings. The primary lessons from past experience are to ensure linkage to care and the efficiency of testing.

2. Improving VL programs {#jia225008-sec-0005}
========================

Over the past decade, public health programs in RLS have introduced and scaled up HIV early infant diagnosis and CD4 testing within many of the same laboratories and health facilities that are currently launching HIV VL testing. Testing coverage and volumes were initially modest -- a few hundred thousand tests -- but reached millions of tests within a few years [3](#jia225008-bib-0003){ref-type="ref"}. By 2015, an estimated 60% of those eligible for CD4 testing had access to the service, and approximately 43% of infants had access to EID testing [12](#jia225008-bib-0012){ref-type="ref"}, [13](#jia225008-bib-0013){ref-type="ref"}. Unfortunately, there is also significant evidence that many test results are not delivered to patients and/or are not used to make the necessary clinical decisions. In other words, despite significant progress, there remains a long way to go before people living with HIV (PLHIV) in RLS have universal access to high‐quality CD4 and EID testing services.

It is expected that over 20 million people will need access to VL testing by 2020 [3](#jia225008-bib-0003){ref-type="ref"}. As VL services will be implemented at the same health facilities and laboratories as CD4 and EID, often utilizing the same staff, infrastructure, logistics, supply chains and data systems, applying lessons learned from CD4 and EID programs may accelerate scale‐up of effective VL testing services (Table [1](#jia225008-tbl-0001){ref-type="table"}).

###### 

Key challenges and potential solutions for the implementation of HIV viral load testing in resource limited settings

  ---------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ensure linkage to care       Faster clinical decision‐making                           Rapid test turn around: Faster sample transport networksElectronic result deliveryPoint‐of‐care testing
                               Improved clinical follow‐up through the cascade of care   Health data systems: Data dashboardsDedicated patient identifiersElectronic patient medical recordsElectronic clinic data management and scheduling
  Improve testing efficiency   Supply chain best practices                               Price‐per‐result supply terms including: InstrumentsReagentsService and maintenanceControlsTest failuresDistribution
                               Tiered diagnostic network                                 Integrated sample referral network: Covers all clinic sitesIncorporates all test typesRegular frequencyLow cost
                               Resource mobilization                                     Forecasting and budgeting: Forecast national test demandMap testing funding and identify gapsUpdate national budgetsIncorporate resource needs for lab systems strengthening
                               Management                                                Build a management team focused on diagnostics service delivery: Operations management teamQuality management team
  ---------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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3. Ensure linkage to care {#jia225008-sec-0006}
=========================

CD4 and EID implementation efforts have been heavily focused on building and equipping laboratories, training staff, and procuring test commodities. These activities were often highly successful, and both CD4 and EID laboratory capacity greatly exceeded test demand in many countries [9](#jia225008-bib-0009){ref-type="ref"}, [10](#jia225008-bib-0010){ref-type="ref"}. The same is true for VL testing; in 2014, VL test volumes in sub‐Saharan Africa outside of South Africa were at 10% of the estimated 2 million test capacity of laboratories in this region [14](#jia225008-bib-0014){ref-type="ref"}. The set‐up of laboratories often occurs faster then health facilities can implement the clinical procedures needed to adopt and use the new tests. Because testing volumes, turn‐around‐time and costs have been the most common metrics for evaluating EID and CD4 programs, a striking fact is often overlooked -- many test results are never delivered to patients and used to guide patient care. In sub‐Saharan Africa, for example an estimated 50% of CD4 and EID test results were not used [15](#jia225008-bib-0015){ref-type="ref"}. Common barriers to the effective utilization of test results include long test turn‐around times leading to loss to follow up, the lack of health data systems, and facility‐level operational challenges described elsewhere in this Supplement [16](#jia225008-bib-0016){ref-type="ref"}, [17](#jia225008-bib-0017){ref-type="ref"}, [18](#jia225008-bib-0018){ref-type="ref"}, [19](#jia225008-bib-0019){ref-type="ref"}, [20](#jia225008-bib-0020){ref-type="ref"}, [21](#jia225008-bib-0021){ref-type="ref"}, [22](#jia225008-bib-0022){ref-type="ref"}, [23](#jia225008-bib-0023){ref-type="ref"}.

3.1. Rapid sample referral and result delivery {#jia225008-sec-0007}
----------------------------------------------

Long test turnaround times (TAT) are particularly devastating in the case of EID, where median TAT remain long, from 20 to 60 days [24](#jia225008-bib-0024){ref-type="ref"}, [25](#jia225008-bib-0025){ref-type="ref"}. The EID cascade has been well described in a range of settings and geographies, including Africa and Asia, and highlights the challenges associated with a failure to effectively link patients to follow‐on care after testing [16](#jia225008-bib-0016){ref-type="ref"}, [17](#jia225008-bib-0017){ref-type="ref"}, [18](#jia225008-bib-0018){ref-type="ref"}, [19](#jia225008-bib-0019){ref-type="ref"}, [20](#jia225008-bib-0020){ref-type="ref"}. For infants tested at four to six weeks of age, EID test results are often returned after the early peak of infant HIV‐related mortality [26](#jia225008-bib-0026){ref-type="ref"}. TAT is also a barrier to utilization of CD4 results, and studies have shown that fewer than 50% of patients received their test results and initiated treatment promptly, when CD4 count thresholds were criteria for ART [22](#jia225008-bib-0022){ref-type="ref"}, [23](#jia225008-bib-0023){ref-type="ref"}.

Several countries have implemented improved sample referral networks and electronic result delivery to reduce TAT. This has included the mapping of sample referral routes and establishing disease‐integrated courier contracts to transport HIV, TB and other clinical specimens, e.g. with the Postal Service or Riders for Health. In Uganda, an extensive and robust sample referral network increased access to EID by 50% and reduced sample transport costs by 50% [24](#jia225008-bib-0024){ref-type="ref"}. Similarly, mHealth initiatives have been implemented for rapid return of test results to clinics using short message system (SMS) printers and dashboards to consolidate and present geospatial testing data to track and follow‐up on defaults to optimal TAT, for example in Kenya, Uganda, Mozambique and South Africa [24](#jia225008-bib-0024){ref-type="ref"}, [25](#jia225008-bib-0025){ref-type="ref"}, [27](#jia225008-bib-0027){ref-type="ref"}. The use of SMS printers for rapid result delivery has been shown to reduce TAT by nearly 50% in Uganda and Mozambique [24](#jia225008-bib-0024){ref-type="ref"}, [25](#jia225008-bib-0025){ref-type="ref"}.

3.2. POC diagnostics {#jia225008-sec-0008}
--------------------

The use of point‐of‐care (POC) diagnostic technologies significantly improves retention in the pre‐ART care cascade. POC testing significantly reduced EID TAT and increased access to ART amongst HIV‐infected infants in Mozambique [28](#jia225008-bib-0028){ref-type="ref"}. Similarly, POC CD4 testing reduced TAT from ten days to less than one day on average [22](#jia225008-bib-0022){ref-type="ref"}. In Mozambique, POC CD4 reduced loss‐to‐follow‐up before ART initiation by 50% [23](#jia225008-bib-0023){ref-type="ref"}. Access to POC VL testing may also help improve the management of treatment failure for patients on ART by dramatically reducing TAT and enabling faster clinical decisions, however studies on this are needed.

3.3. Data systems to improve the cascade of care {#jia225008-sec-0009}
------------------------------------------------

Other critical enablers of effective test utilization include integrated data and clinical systems that improve the cascade of care from the identification of eligible patients, the provision of testing, and delivery of results back to the health facility and patient. This enables results to be used swiftly to make clinical decisions. It is therefore important to build diagnostic systems with patient care in mind, ensuring that delivery of results to health facilities is well integrated with clinical patient management and well synchronized with the patient pathway of care. Several interventions have been shown to improve the cascade of clinical care from testing through linkage to care, including clinical quality improvements such as the use of SMS result delivery to clinics or patients, and active patient follow‐up by community health workers [29](#jia225008-bib-0029){ref-type="ref"}, [30](#jia225008-bib-0030){ref-type="ref"}, [31](#jia225008-bib-0031){ref-type="ref"}, [32](#jia225008-bib-0032){ref-type="ref"}, [33](#jia225008-bib-0033){ref-type="ref"}, [34](#jia225008-bib-0034){ref-type="ref"}, [35](#jia225008-bib-0035){ref-type="ref"}. In Mozambique, SMS result delivery to clinics was associated with a 20% increase in receipt of test results by caregivers, and a three‐fold decrease in testing errors [25](#jia225008-bib-0025){ref-type="ref"}, [36](#jia225008-bib-0036){ref-type="ref"}. Data systems that enable the follow‐up of patients through the cascade of care have been shown to improve overall clinical outcomes, for example in South Africa where visual dashboards enabled data‐driven interventions to improve health program performance against key indicators for the prevention of mother to child infection [27](#jia225008-bib-0027){ref-type="ref"}.

3.4. Application to VL programs {#jia225008-sec-0010}
-------------------------------

It will be useful to draw from the above interventions that have proven to be successful with CD4 and EID programs so that steps can be taken early in VL implementation to establish effective practices. In particular, testing programs need to ensure that VL testing is well integrated with ART failure management processes, for example that test TAT do not introduce long delays in detecting and confirming failure, and that results are delivered to clinicians and patients in order for timely follow‐on care, such as enhanced adherence support and/or a drug regimen switch. VL monitoring and evaluation programs should also include metrics such as testing coverage, test TAT, test delivery to clinics and patients, and test utilization to guide ART management. In many settings, VL programs can leverage existing EID and CD4 sample referral and electronic results delivery networks. The utility of POC VL still needs further investigation, but it is possible that the availability of rapid VL results may improve patient adherence, differentiated care, and reduce program costs (Table [1](#jia225008-tbl-0001){ref-type="table"}).

4. Improve testing efficiency {#jia225008-sec-0011}
=============================

The establishment of large scale CD4 and EID testing programs in low‐resource settings over the past 15 years faced many challenges [9](#jia225008-bib-0009){ref-type="ref"}, [11](#jia225008-bib-0011){ref-type="ref"}. As a result the focus of these programs was often on ensuring test access. As access has improved, attention is turning to testing efficiency in order to ensure the clinical impact of testing and to reduce costs. Key interventions to improve efficiency are described below (Table [1](#jia225008-tbl-0001){ref-type="table"}).

4.1. Procurement and supply chain {#jia225008-sec-0012}
---------------------------------

Large‐scale VL testing programs will consume significant quantities of diagnostic commodities run on networks of instruments. Ensuring the reliable and efficient supply of testing products and preventing breakdowns of instruments requires some of the innovative approaches that have been developed within EID and CD4 testing programs. At the outset of these programs, test kit and instrument costs were high, test procurement was highly disaggregated across government, donors and implementing partners, and stock outs and instrument breakdowns were frequent. Many of these challenges have not yet been resolved; a recent WHO survey found approximately 10% of instruments were not in use due to stock‐outs, breakdowns or non‐installation [37](#jia225008-bib-0037){ref-type="ref"}. Two supply chain innovations -- global access price deals and bundled agreements -- have been implemented for the CD4 and EID markets, and are highly relevant to VL.

Global access price deals are negotiated centrally and provide equitable access to low pricing for all public sector buyers irrespective of procurement volume. This allows smaller countries with limited purchasing power to access the same pricing as high volume countries. Price reductions of 30% to 50% for CD4 and EID tests have resulted in substantial commodity budget savings for countries and donors around the world, and have helped expand access to these tests [38](#jia225008-bib-0038){ref-type="ref"}, [39](#jia225008-bib-0039){ref-type="ref"}. Access pricing is also available for certain VL test suppliers and this has helped make VL more accessible [40](#jia225008-bib-0040){ref-type="ref"}.

Supply chain initiatives can have significant impact, reducing costs and increasing health product availability [41](#jia225008-bib-0041){ref-type="ref"}. For diagnostics, supply terms such as all‐in or price‐per‐result (incorporating instruments, reagents, training, quality assurance, distribution and test failures), reagent rental agreements that remove up‐front instrument capital cost, and bundled reagent‐maintenance agreements that eliminate separate maintenance contracts, have been designed and implemented for EID and CD4 testing networks. These are designed to reduce costs and financial barriers, improve procurement flexibility, efficiency and supplier accountability, and reduce instrument down‐time and stock‐outs. They also establish partnerships between suppliers and procurers and encourage more coordinated procurement. Coordinated procurement, whereby testing volumes and ordering schedules across procurers and over time are consolidated to negotiate improved supplier terms, has been effectively used to improve CD4 and EID supply chains.

The Global Fund has established framework agreements with major VL suppliers that provide mechanisms for standardized access to bundled supply terms [42](#jia225008-bib-0042){ref-type="ref"}. In addition, several national testing programs, for example Brazil, South Africa, Kenya and Uganda, have implemented bundled agreements for VL testing. These build on procurement principles and mechanisms developed with large‐scale CD4 and EID programs. Instead of procuring instruments, testing kits, and annual instrument service and maintenance separately, national testing volumes have been consolidated (by the government or through a procurement consortium of government, donors and implementing partners), and a single contract for supply of instruments, reagents and service and other test components at prices lower than disaggregated procurement. Bundled procurement helps ensure service and maintenance is always accessible; a critical need in many countries. The recent WHO survey found that most CD4 instruments in public laboratories were not covered by service and maintenance contracts, were not serviced regularly and breakdowns were frequent [37](#jia225008-bib-0037){ref-type="ref"}. Bundled procurement requires well‐established forecasts and regular ordering cycles, which help ensure reliable test manufacture and supply. Bundled agreements also provide the flexibility to switch, if needed, to more competitive suppliers at the end of each contract because the instruments were not purchased. For example, bundled agreements have been used in South Africa and Brazil for over ten years and have enabled easier switches in testing technologies without having to formally retire instruments and the financial hurdle of paying for new equipment up front [14](#jia225008-bib-0014){ref-type="ref"}.

Although they are valuable tools for optimizing supply chain, bundled agreements have been infrequently used for VL testing programs, partly due to unconsolidated procurement or difficulty with undertaking multi‐year procurement commitments. As VL testing programs scale‐up to meet growing demand, the need for more effective procurement mechanisms and better coordinated procurement across buyers will also grow. Given the relatively high reagent and capital costs, and the technical complexity of VL instruments, and hence need for routine service by an engineer, carefully negotiated bundled agreements and access pricing will likely be useful measures to increase the sustainability and reliability of large‐scale testing programs.

4.2. Laboratory networks {#jia225008-sec-0013}
------------------------

Health systems in many LRS often have limited ability to support large testing networks [43](#jia225008-bib-0043){ref-type="ref"}, [44](#jia225008-bib-0044){ref-type="ref"}. In particular, instrument technology‐based testing programs require substantial supportive systems. To ensure widespread access, test networks are required, comprising a tiered network of laboratories servicing a wider network of health facilities. The functioning of such networks relies heavily on testing systems such as sample referral to ensure access to laboratory capacity over wide geographic areas, health data systems to ensure rapid dissemination of test results for clinical, programmatic and surveillance uses, and quality assurance to ensure reliable results irrespective of testing location [45](#jia225008-bib-0045){ref-type="ref"}, [46](#jia225008-bib-0046){ref-type="ref"}. Laboratory networks have been strengthened in numerous countries, establishing active sample referral and results delivery connections between central and decentralized levels of the health care system. For example, Mali, Burkina Faso and Senegal through the Resaolab program have improved surveillance and outbreak detection readiness, in line with the eight WHO laboratory requirements of the International Health Regulations and laboratory readiness requirements of the Global Health Security Agenda [47](#jia225008-bib-0047){ref-type="ref"}.

The rational deployment of testing technologies within the networks is a key factor for efficiency. A common feature of CD4 and EID testing networks to date has been over‐capacity and under‐utilization of the instrument base. A 2013 WHO survey in 127 countries identified a surplus of global CD4 capacity, sufficient instrumentation to conduct 4.6 tests per year for every person living with HIV, and 12.8 tests/year for every person on ART, as opposed to the 1 to 2 tests per year required at that time [37](#jia225008-bib-0037){ref-type="ref"}. Capacity utilization across instruments was only 13.7%. At the start of scale‐up programs it was likely common to deploy excess instruments to ensure no capacity limitations. As testing programs mature, there are opportunities to build more efficient networks and to increase instrument utilization. The lessons for VL deployment are to start testing programs by placing devices with appropriate capacity at each testing location. For example, placing high throughput instruments at central test demand locations and lower throughput devices at smaller sites with robust sample referral linkages that maximize instrument utilization and therefore, the return on the investment made for each instrument [48](#jia225008-bib-0048){ref-type="ref"}. This requires data on testing current and projected needs across the network of health facilities, the mapping of sample referral routes, and coordinated national instrument procurement and deployment plans [24](#jia225008-bib-0024){ref-type="ref"}, [49](#jia225008-bib-0049){ref-type="ref"}. Several tools now exist to help optimize testing networks, including the USAID‐developed LabEQIP tool [50](#jia225008-bib-0050){ref-type="ref"}.

4.3. Resource mobilization {#jia225008-sec-0014}
--------------------------

One of the key lessons from the scale‐up of CD4 and EID programs is while significant donor funding has gone into laboratory services over the past decade, long‐term national investment in laboratory testing is needed. Effective national laboratory systems such as logistic and health data systems are often under‐funded and not fully part of routine service. This is partly because the full costs of testing services, especially when new diagnostics are being rapidly scaled up, and the financial resources needed to ensure access to essential diagnostic tests at national scale are difficult to estimate and track. As a result, large‐scale public testing programs such as VL face risks and may be unstable and unsustainable unless appropriate investments are made in testing and necessary supportive systems. For example, in Zimbabwe despite a goal of 21% VL coverage in 2015, only 5.6% test coverage was achieved due to challenges in resource mobilization and related factors [49](#jia225008-bib-0049){ref-type="ref"}. For fast growing testing programs such as VL, test projections need to routinely inform national laboratory budgets to reduce the risk of funding shortfalls. Data systems such as test dashboards, that are connected to laboratory and POC instruments, can track test volumes and utilization in real time and produce consumption data to better inform national HIV diagnostics quantification exercises, for example using the USAID‐developed ForLab tool [50](#jia225008-bib-0050){ref-type="ref"}.

In addition, the investment case for laboratory systems strengthening needs to be more clearly articulated so that sustainable funding for these systems can be established. Investments in scaling up CD4 and EID in many countries have often included laboratory system strengthening programs for logistics, data and quality, providing an opportunity to build on these investments to support VL testing programs [9](#jia225008-bib-0009){ref-type="ref"}. Guidelines of the Global Fund clearly elaborate a comprehensive range of critical laboratory strengthening investments that countries can make using Global Fund resources, including human resource capacity development, procurement and equipment management systems, quality improvement, development of tiered laboratory networks, and data systems [51](#jia225008-bib-0051){ref-type="ref"}.

4.4. Management {#jia225008-sec-0015}
---------------

The unprecedented scale of CD4 and EID testing programs has highlighted the need for stronger management within public laboratory programs, both operational and quality management. Laboratory quality improvement programs such as the Strengthening Laboratory Management Towards Accreditation (SLMTA), developed by the United States Centers for Disease Control and Prevention, and the WHO Strengthening Laboratory Improvement Towards Accreditation (SLIPTA) program supported by the African Society for Laboratory Medicine have increased quality management skills and have established a growing trend towards accreditation in public laboratories [52](#jia225008-bib-0052){ref-type="ref"}. Countries such as India, Ethiopia, Ghana, Nigeria, and the Caribbean region have made significant steps towards strengthening quality management skills and laboratory accreditation [53](#jia225008-bib-0053){ref-type="ref"}, [54](#jia225008-bib-0054){ref-type="ref"}, [55](#jia225008-bib-0055){ref-type="ref"} Although quality improvement systems are still to fully establish across a wider range of countries, these quality initiatives provide a foundation that VL programs will be able to leverage to ensure reliable testing.

Tiered networks of laboratories have significant operational management needs to ensure efficiency; however most leaders of public health laboratory networks are not trained in operations [56](#jia225008-bib-0056){ref-type="ref"}. This includes the infrastructure management, i.e. ensuring adequate physical space and equipment within laboratories, financial management including budgeting, supply chain and distribution systems, logistics and data systems, and monitoring and evaluation. Improved operations management within laboratory networks may improve adherence to performance standards and ensure a service‐oriented relationship with health facilities and other stakeholders in testing services. Many of the systems weaknesses observed with CD4 and EID scale‐up and described above, such as gaps in supply chain, slow sample referral and test turn around times, and limited use of data systems may be related to inadequate operations management capacity and skills. The strengthening of this capacity within public departments responsible for laboratory services may help ensure more effective delivery of diagnostic tests within the parameters needed for clinical management and improved patient outcomes.

5. Conclusions {#jia225008-sec-0016}
==============

The global scale‐up of EID and CD4 testing services has established important systems and experience with large‐scale public health testing programs. It has also identified weaknesses in diagnostic access that may ultimately limit the success of these programs, as well as new tests such as VL. There are many innovations and best practices from these initial large‐scale testing programs to learn from, as well as persistent challenges to overcome. There are critical needs and opportunities in linkage to care and testing efficiency, including improved data and sample referral systems, POC tests, improved supply terms, and more effective laboratory network management that are important to address during the scale‐up of HIV VL testing programs in resource limited settings (Table [1](#jia225008-tbl-0001){ref-type="table"}). Learning from prior experiences with CD4 and EID test scale‐up will help ensure accessible and reliable VL services and help overcome major test implementation barriers.
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